• PExA AB flagged three clinical research abstracts using its small-airway sampling technology for presentation at ERS Congress 2026.
• Results have not been presented yet; presentations are scheduled in Barcelona on Sept. 5-9, 2026.
• Studies indicate the platform can help separate pulmonary fibrosis patients from healthy controls, supporting biomarker-driven disease assessment.
• COPD research points to links between exhaled particles, biomarkers, disease severity, lung function, supporting monitoring of distal airway changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PExA AB published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.